drugset

drugset / Trial / NCT00222131

Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients

NCT00222131 ↗

Phase 2 Completed 73 enrolled University of Kansas Medical Center AstraZeneca · collab

RandomizedFactorialDouble-blindTreatment

Summary

Inhibition of gastric acid is the key to satisfactory relief of symptoms with esomeprazole in NUD patients

Timeline

Start: 2003-10
Primary completion: 2008-01
Completion: 2008-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Esomeprazole	Small molecule	40 mg	—

Indications